UBS Group’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-10,431
| Closed | -$410K | – | 10348 |
|
|
2023
Q2 | $410K | Sell |
10,431
-100,451
| -91% | -$3.55M | ﹤0.01% | 4988 |
|
|
2023
Q1 | $2.7M | Sell |
110,882
-159,395
| -59% | -$3.49M | ﹤0.01% | 3108 |
|
|
2022
Q4 | $5.79M | Buy |
270,277
+186,872
| +224% | +$3.99M | ﹤0.01% | 2355 |
|
|
2022
Q3 | $1.5M | Sell |
83,405
-117,189
| -58% | -$1.54M | ﹤0.01% | 3416 |
|
|
2022
Q2 | $1.93M | Buy |
200,594
+178,060
| +790% | +$2.23M | ﹤0.01% | 3183 |
|
|
2022
Q1 | $379K | Sell |
22,534
-2,226
| -9% | -$32.9K | ﹤0.01% | 4892 |
|
|
2021
Q4 | $414K | Buy |
24,760
+3,693
| +18% | +$60.5K | ﹤0.01% | 5128 |
|
|
2021
Q3 | $342K | Sell |
21,067
-850
| -4% | -$9.25K | ﹤0.01% | 4964 |
|
|
2021
Q2 | $138K | Buy |
21,917
+878
| +4% | +$5.66K | ﹤0.01% | 5627 |
|
|
2021
Q1 | $130K | Buy |
21,039
+14,981
| +247% | +$90.9K | ﹤0.01% | 5756 |
|
|
2020
Q4 | $42K | Buy |
6,058
+4,768
| +370% | +$30.5K | ﹤0.01% | 6345 |
|
|
2020
Q3 | $7K | Sell |
1,290
-193
| -13% | -$920 | ﹤0.01% | 7158 |
|
|
2020
Q2 | $8K | Hold |
1,483
| – | – | ﹤0.01% | 7168 |
|
|
2020
Q1 | $5K | Buy |
1,483
+1,000
| +207% | +$5.84K | ﹤0.01% | 7340 |
|
|
2019
Q4 | $4K | Hold |
483
| – | – | ﹤0.01% | 7692 |
|
|
2019
Q3 | $1K | Sell |
483
-200
| -29% | -$233 | ﹤0.01% | 7873 |
|
|
2019
Q2 | $1K | Hold |
683
| – | – | ﹤0.01% | 7759 |
|
|
2019
Q1 | $1K | Sell |
683
-404
| -37% | -$565 | ﹤0.01% | 7586 |
|
|
2018
Q4 | $2K | Buy |
1,087
+553
| +104% | +$1.07K | ﹤0.01% | 7832 |
|
|
2018
Q3 | $1K | Buy |
534
+45
| +9% | +$112 | ﹤0.01% | 7873 |
|
|
2018
Q2 | $1K | Hold |
489
| – | – | ﹤0.01% | 7860 |
|
|
2018
Q1 | $1K | Sell |
489
-1,460
| -75% | -$4.23K | ﹤0.01% | 7682 |
|
|
2017
Q4 | $6K | Buy |
1,949
+1,219
| +167% | +$3.43K | ﹤0.01% | 7326 |
|
|
2017
Q3 | $2K | Hold |
730
| – | – | ﹤0.01% | 7502 |
|
|
2017
Q2 | $2K | Sell |
730
-109
| -13% | -$297 | ﹤0.01% | 7416 |
|
|
2017
Q1 | $3K | Sell |
839
-48,406
| -98% | -$205K | ﹤0.01% | 7213 |
|
|
2016
Q4 | $238K | Buy |
49,245
+36,877
| +298% | +$1.09M | ﹤0.01% | 4672 |
|
|
2016
Q3 | $571K | Sell |
12,368
-4,581
| -27% | -$258K | ﹤0.01% | 3835 |
|
|
2016
Q2 | $865K | Buy |
16,949
+8,428
| +99% | +$419K | ﹤0.01% | 3504 |
|
|
2016
Q1 | $361K | Sell |
8,521
-33,371
| -80% | -$1.7M | ﹤0.01% | 4035 |
|
|
2015
Q4 | $3.29M | Buy |
41,892
+36,856
| +732% | +$2.13M | ﹤0.01% | 2333 |
|
|
2015
Q3 | $204K | Buy |
5,036
+3,156
| +168% | +$167K | ﹤0.01% | 4628 |
|
|
2015
Q2 | $98K | Buy |
1,880
+1,280
| +213% | +$63.7K | ﹤0.01% | 5426 |
|
|
2015
Q1 | $28K | Buy |
600
+265
| +79% | +$13.8K | ﹤0.01% | 6624 |
|
|
2014
Q4 | $15K | Buy |
+335
| New | +$14.1K | ﹤0.01% | 8038 |
|
UBS Group's ISEE Position: Q3 2023 in Review
UBS Group sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 10,431 shares — an estimated $410K sold.
UBS Group first reported a position in ISEE in Q4 2014 and held it in 35 quarters. The position peaked at $5.79M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- UBS Group reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 10,431 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $410K.
- UBS Group first reported a position in IVERIC bio, Inc. Common Stock in Q4 2014 and held it in 35 quarters.
- UBS Group's IVERIC bio, Inc. Common Stock position peaked at $5.79M in Q4 2022.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.